We hypothesize that SIRPγ expression on immune cells may be correlated with specific stages of T1D development in a manner governed by genetic risk variants in SIRPG, and thus, could be used as a biomarker of disease progression in conjunction with C-peptide and AAbs (12, 93, 94). This evidence concerns the gene SIRPG and type 1 diabetes mellitus.